)1 re 20 re	gulations.)16/679 or ports of sa	During the other int other data	ge, processing and his process, perso ernational legisla Pharmaceutic	nal data is tion. As an	protect addition	ed in accorda	nce to on, cert	the General D ain personal d	ata Protect ata is made	ion Reg	gulations GDP	R, REGU	JLATION (ÉU	J)	E)
	•						1051105	Auverse	Lven	i make ru	1 111				1		
		Awara	Receipt Date (LSU or LSU Representative's Awareness Date - DD-MMM-YYYY format): Local Case Number														
	completed by the Local Safety Unit (PV								•						-		•
	team) only			t (LSU) - ⁻	Territory/Compa	ny name									<u></u>		
	L. REPORTER CONT											1					
Report	ter and Institution N	ame	Stree	et Addres	S		City		St	ate/Country		Telep	phone /Fax	Em	ail		
Renor	tor type: Dhusid	ian	Pharmaci	ct	Other Healthear	Drofossia	nal (UC			r/Othor Non J			r Other				
	Reporter type: Physician Pharmacist Other Healthcare Professional (HCP) Consumer/Other Non-HCP Lawyer Other: PART 2. PATIENT INFORMATION																
Patien		Pregnant	P	aco / Eth	nicity		Woig	ht		Height		DOB		Age (in	vears) or Age	Group	
Initials		Fieghant		Race / Ethnicity Weight Height DOB		MM-YYYY	Age (in years) or Age Group (only complete if Year of Birth is unavailable			navailable)							
								kį	g lb		cm in				NNeonate Adult		Child
	3. ADVERSE EVENT I		ON (optor	diagnosi	ic and cumptoms							1			Addit	Elderly	Unknown
	se Event		ON (enter	-	ousness Criteria		nt Outco		•	ionship	Time from	Last	Onset Date	and Tim	e	Event End	Date and
	le diagnosis and/or	symptom if	available)						Between AE and Admin to Onset			(DD-MMM	(DD-MMM-YYYY		Time (DD-	МММ-ҮҮҮҮ	
									Suspe	ect Drug	(latency)		HH:MM AN	1/РМ)		HH:MM A	M/PM)
ļ																	
•				•			•							·			
PART	4. SUSPECT DRUG I	NFORMATI	ON														
Produ	ıct Info	Batch No.	/ Exp.D	Date	Exam Type/	Indicatio		Start Date a	nd S	top Date and	Dose (Un		Route	Fc	ormulation		
		Lot No.			Procedure	procedu (if know)		Time	Т	ïme	Frequen	су					
Trade	or Generic Name:						,			ongoing							

Trade or Generic Name:			ongoing		
Prev. Exp: Y N Tolerance: Y N					
Trade or Generic Name:			ongoing		
Prev. Exp: Y N Tolerance: Y N					

Document No. PVPI_SPV.19.01_A01 Version 7.0	The collection, storage, processing and worldwide reporting of personal data connected to adverse events is required by international drug safety regulations. During this process, personal data is protected in accordance to the General Data Protection Regulations GDPR, REGULATION (EU) 2016/679 or other international legislation. As an additional precaution, certain personal data is made anonymous in, or withheld from, individual reports of safety data.	E)
Title:	GE Healthcare Pharmaceutical Diagnostics Adverse Event Intake Form	

PART 5. ADDITIONAL DETAILS OF THE ADVERSE EVENT (Include all available details about clinical course and any other details not specified in other fields. Include treatment for AE, if applicable. For treatment medication, include indication, start and stop dates, and route. For non-interventional studies, include Study ID, Patient ID, and Center or Site ID.)

PART 6. CONCOMITANT MEDICATION INFORMATION (Include prescription, over-the-counter, and herbal medications)

	· · · · · ·	-			
Trade name or Generic name	Indication	Start date	Stop Date (enter "ongoing" if no stop date)	Dose (Units) & Frequency	Route

PART 7. RELEVANT MEDICAL CONDITIONS / HISTORY					PART 8. SPECIFIED RISK FACTORS							
Condition (if information does not fit, add	Medical Hist	ory (MH) OR	Start Date	Stop Date	ľ		Risk Fa	actor?		Start Date	Stop date	Specify allergy/
to 'Additional Details of the AE' section)	Current Con	dition (CC)										Comments
	MH	CC				Allergies	Y	Ν	Unk			
	MH	CC			ŀ	Asthma	Y	Ν	Unk			
	MH	CC				Dehydration	Y	Ν	Unk			
	MH	CC				Renal Impairment	Y	Ν	Unk			

PART 9. RELEVANT DIAGNOSTIC TESTS (INCLUDING VITAL SIGNS)						
Test name	Date	Results (include units)	Lab normal values (include units)			

NAME	SIGNATURE	DATE

Please send completed form to the Central Safety Unit (CSU) at gpv.drugsafety@ge.com

Gender	Pregnant	Race / Ethnicity	Seriousness Criteria
 Male Female Other Unknown 	 Yes No Unknown 	 Caucasian Black Asian Other African American American Indian Alaska Native Native Hawaiian Other Pacific Islander White Hispanic Unknown 	 Death Life-threatening Hospitalization Prolonged Hospitalization Disability Congenital Anomaly Important Medical Event Non-serious Unknown

Drop-down Menu Quick Reference

Outcome	Relationship to Suspect Product	Formulation
 Recovered Recovering Not Recovered Recovered with Sequelae Death Unknown 	 Not Related Not Reported Related 	 Solution for Injection Solution for injection via pre-filled syringe Oral Solution Other (specify in Part 5) Unknown

Date Format Quick Reference

dd-Mmm-yyyy

Receipt Date LSU or LSUs Representative's awareness date